Autopsy report · NCT02749526

Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial

“low accrual rate”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 8 months before it stopped.
• 70 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Sponsor type

University, hospital or other

Conditions

Esophageal

Interventions

"Endostar"; Liposo; cisplatin; Gimeracil and Oteracil Potassium （Tegafur）

Participants

70 (planned, not actual)

Sites

1

Countries

China

Trials that died the same way

• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (92% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• Osteoarthritis Shoulder Injection Study
  “insufficient rate of accrual” (87% match in meaning)
• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (85% match in meaning)
• Education for Prevention of Melanoma in Hispanic Populations
  “Low/slow accrual” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.